Chai Discovery Raises $130M Series B at $1.3B Valuation
▼ Summary
– Chai Discovery, a biotech startup, raised $130 million in a Series B round, achieving a $1.3 billion valuation with backing from investors including OpenAI.
– The funding round was led by General Catalyst and Oak HC/FT, bringing the company’s total funding to over $225 million.
– The company uses AI foundation models to predict biochemical interactions and aims to create a “computer aided design suite” for molecules.
– Its latest AI model, Chai 2, is reported to significantly improve success rates for designing custom antibodies from scratch.
– The CEO, Josh Meier, has a background in machine learning from Facebook and OpenAI, and the company was founded in 2024.
The biotech firm Chai Discovery has secured a major $130 million investment in its latest funding round, propelling the company to a valuation of $1.3 billion. This significant Series B financing underscores the growing confidence in artificial intelligence as a transformative force for accelerating the pace of drug development. The investment was spearheaded by venture capital leaders General Catalyst and Oak HC/FT, with participation from a notable group including Menlo Ventures, OpenAI, Dimension, and Thrive Capital. This latest capital infusion brings the startup’s total funding to over $225 million, providing substantial resources to advance its ambitious AI-driven research platform.
Chai Discovery operates within the rapidly expanding field of AI-powered biotechnology, which aims to drastically shorten the traditional timelines and costs associated with discovering new therapeutics. The company’s core mission is to develop what it describes as a comprehensive “computer-aided design suite” for molecular engineering. This involves creating sophisticated foundation models specifically calibrated for the complexities of drug discovery. These AI systems are trained to predict intricate interactions between biochemical compounds, enabling researchers to intelligently reprogram molecules for therapeutic purposes.
The startup’s technological progression is marked by the release of its AI models. Following the introduction of the Chai 1 model last year, the company has now launched Chai 2, its most advanced platform to date. Early results are promising, particularly in the specialized area of de novo antibody design. This process involves constructing custom antibodies entirely from scratch, rather than modifying existing ones, which represents a formidable challenge in biopharmaceuticals. Chai reports that its latest model demonstrates markedly higher success rates in this domain compared to conventional methods.
“Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach,” stated Josh Meier, Chai’s co-founder and CEO. Meier’s background blends machine learning expertise with practical industry experience, having previously contributed to research and engineering efforts at Facebook and OpenAI. Founded in 2024, Chai Discovery is a relatively young company that has rapidly attracted attention and capital from top-tier investors, reflecting the high stakes and potential of its AI-first approach to one of science’s most critical endeavors.
(Source: TechCrunch)
